About Fina Biosolutions
Fina Biosolutions is a company based in Rockville (United States) founded in 2006.. Fina Biosolutions has raised $3 million across 4 funding rounds from investors including NIH, HHS and SK bioscience. Fina Biosolutions offers products and services including CRM 197, Functionalized Dextrans, and Conjugation Services. Fina Biosolutions operates in a competitive market with competitors including Proteros, Neovacs, Nabla, Biomatter and VERAXA, among others.
- Headquarter Rockville, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Fina Biosolutions, Llc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$3 M (USD)
in 4 rounds
-
Latest Funding Round
$3 M (USD), Seed
Oct 08, 2024
-
Investors
NIH
& 2 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Fina Biosolutions
Fina Biosolutions offers a comprehensive portfolio of products and services, including CRM 197, Functionalized Dextrans, and Conjugation Services. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Protein used as carrier for conjugate vaccines in preclinical and clinical applications.
Dextrans for polysaccharide conjugation and characterization in biotech services.
Services for vaccine conjugation and training programs.
Funding Insights of Fina Biosolutions
Fina Biosolutions has successfully raised a total of $3M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $3 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Seed — $3.0M
-
First Round
First Round
(20 Apr 2020)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2024 | Amount | Seed - Fina Biosolutions | Valuation | SK bioscience |
|
| Jan, 2024 | Amount | Grant - Fina Biosolutions | Valuation |
investors |
|
| Jan, 2024 | Amount | Grant - Fina Biosolutions | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Fina Biosolutions
Fina Biosolutions has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and SK bioscience. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Innovative vaccines are developed and manufactured by SK bioscience.
|
Founded Year | Domain | Location | |
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location | |
|
Public health and human services are overseen by HHS.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Fina Biosolutions
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Fina Biosolutions
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Fina Biosolutions Comparisons
Competitors of Fina Biosolutions
Fina Biosolutions operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Proteros, Neovacs, Nabla, Biomatter and VERAXA, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Drug discovery services are provided to researchers in protein biochemistry.
|
|
| domain | founded_year | HQ Location |
Vaccine manufacturing services are provided by Neovacs CDMO.
|
|
| domain | founded_year | HQ Location |
Synthetic biology platform for functional protein identification is provided.
|
|
| domain | founded_year | HQ Location |
Provider of synthetic biology and AI-based technology for generative protein design
|
|
| domain | founded_year | HQ Location |
Antibody therapeutics for cancer treatment are developed via microfluidic screening.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Fina Biosolutions
Frequently Asked Questions about Fina Biosolutions
When was Fina Biosolutions founded?
Fina Biosolutions was founded in 2006 and raised its 1st funding round 14 years after it was founded.
Where is Fina Biosolutions located?
Fina Biosolutions is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Is Fina Biosolutions a funded company?
Fina Biosolutions is a funded company, having raised a total of $3M across 4 funding rounds to date. The company's 1st funding round was a Grant of $297.81K, raised on Apr 20, 2020.
What does Fina Biosolutions do?
Founded in 2006 in Rockville, United States, Fina Biosolutions operates in the biotechnology sector with a focus on bioconjugation services for vaccine discovery, development, and commercialization. Technology has been licensed to manufacturers such as GSK and Serum Institute of India. Through subsidiary Fina Reagents, proteins, polysaccharides, and antibodies related to vaccines and infectious diseases are sold. Protein purification services are also provided, alongside collaborations with drug developers.
Who are the top competitors of Fina Biosolutions?
What products or services does Fina Biosolutions offer?
Fina Biosolutions offers CRM 197, Functionalized Dextrans, and Conjugation Services.
Who are Fina Biosolutions's investors?
Fina Biosolutions has 3 investors. Key investors include NIH, HHS, and SK bioscience.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.